| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10371 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-644
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2017-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_208b6ce3dc06bf3c9998ba609b7db3dc |
| publicationDate |
2019-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019201551-A1 |
| titleOfInvention |
Pulmonary targeted cas9/crispr for in vivo editing of disease genes |
| abstract |
An adenovirus vector comprising: a pulmonary targeting coding sequence, CRISPR components such as a Cas9 coding sequence, and a guideRNA coding sequence which can be used for gene therapy. The adenovirus can be a gorilla adenovirus, and can include a pulmonary cell targeting sequence such as an MBP targeting ligand coding sequence. The adenovirus can be targeted to pulmonary epithelium with a vascular specific promoter and integrin targeting peptides incorporated into a viral knob. The adenovirus can be used to introduce serum proteins via the pulmonary epithelium. Hemophilia can be treated by adenoviral introduction of factor VIII or factor IX. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11401529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114317536-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021082784-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077156-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11130968-B2 |
| priorityDate |
2016-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |